| Objective. To compare ocular diseases in visual acuity gain and intraocular pressure rise after intravitreal high-dose injection of triamcinolone acetonide (IVTA).
Participants. The retrospective case series study included 359 eyes with diabetic macular edema (n=102), progressive exudative age-related macular degeneration mostly with non-classic subfoveal neovascularization (AMD) (n=216), uveitis (n=10), branch retinal vein occlusion (BRVO) (n=12), central retinal vein occlusion (CRVO) (n=12), and pseudophakic cystoid macular edema (n=7). All eyes received a single intravitreal injection of about 20 mg triamcinolone acetonide.
Results. Maximal increase in visual acuity was significantly lower in the AMD group (-0.10 0.30 logMar units) than in the diabetic macular edema group (-0.24 0.22 logMar units) (p<0.001), the BRVO group (-0.22 0.23 logMar units) (p=0.032), the CRVO group (-0.26 0.26 logMar units) (p=0.032), the uveitis group (-0.29 0.19 logMar units), and the pseudophakic cystoid macular edema (-0.30 0.22 logMar units) (p=0.042). Rise in intraocular pressure was significantly the highest in the uveitis group (11.3 7.0 mm Hg) than in the other study groups which did not vary significantly in the rise of intraocular pressure.
Conclusions. A visual acuity increase after intravitreal triamcinolone is highest in non-ischemic diseases with an intraretinal macular edema, lower in partially ischemic diseases with intraretinal macular edema, and lowest in diseases with a primarily subretinal location of the disease. The intraocular pressure rise may be higher in relatively young patients with uveitis than in elderly patients with other reasons for macular edema.
|
网友评论：（只显示最新10条。评论内容只代表网友观点，与本站立场无关！）